(lp0
S'Supernus: Label Expansion, Trokendi Settlement Catalysts For More Upside Seeking Alpha - Mar 16, 2017 The company guided for 2017 sales in the $265-275 million range, which is right in line with my estimate range for the year.'
p1
aS'Supernus Pharmaceuticals: The Investment Case Improves Seeking Alpha - Dec 15, 2016 Tier 2 biotech concern Supernus Pharmaceuticals received some good news regarding key patent litigation this week. This the latest piece of positive news for ... This removes an overhang from the company and the stock. Oxtellar XR is the lesser of two ...'
p2
aS'Supernus Pharmaceuticals Offers A Rare Opportunity For Investors Seeking Alpha - Jan 5, 2017 Supernus Pharmaceuticals  is a rarity among the thousands of publicly-traded biotechnology firms; it has approved products, revenue and earnings.'
p3
aS'Stock Returns: Supernus Pharmaceuticals Inc  is Beating SciClone ... CML News - 10 hours ago This is a snapshot to compare the stock returns for SciClone Pharmaceuticals Inc  versus Supernus Pharmaceuticals Inc  . The stock return points we compare look at the last three-months, six-months and twelve-months.'
p4
aS'Supernus Is Moving In The Right Direction Seeking Alpha - Jan 26, 2017 Supernus Is Moving In The Right Direction ... The marketed product portfolio continues to grow at a healthy pace and the company is on its way to becoming significantly profitable in 2017 considering the growing revenues and solid operating leverage.'
p5
aS"Supernus Pharmaceuticals'  CEO Jack Khattar on Q3 2016 Results ... Seeking Alpha - Nov 18, 2016 Good morning everyone, and thank you for joining us today for Supernus Pharmaceuticals' third quarter 2016 business update conference call."
p6
aS'Supernus: Reasonable Valuation And Strong Future Growth Seeking Alpha - Oct 5, 2016 Supernus Pharmaceuticals  has already proven itself as a profitable generic drug maker with positive cash flow.'
p7
aS'Cadila inks pact with Supernus Pharma to settle patent issue Moneycontrol.com - Mar 7, 2017 Cadila Healthcare, along with subsidiary Zydus Pharmaceuticals  Inc, have finalised an agreement with Supernus Pharmaceuticals Inc to settle all outstanding patent litigation related to Trokendi XR  extended-release capsules, Cadila&nbsp;...Analyst Activity  Cantor Fitzgerald Reiterates Buy on Supernus ... - Market ExclusiveSupernus Pharma  Settles Trokendi XR Patent Litigation With Zydus - StreetInsider.com'
p8
aS'Is Supernus Accurately Evaluating The Market Opportunity? Seeking Alpha - Nov 28, 2016 Supernus Pharmaceuticals  was supposed to release its results for the three months ended September 30, 2016, in late November.'
p9
aS'Supernus - SPN-812 Results And Thesis Update Seeking Alpha - Oct 14, 2016 The study met its primary endpoint and the effect size was really good for a non-stimulant product. The results support the case for SPN-812 being the dominant non-stimulant product in the ADHD market.'
p10
a.